Regeneron Pharmaceuticals Aktie News

New presentations include final 64-week results from the Phase 3 QUASAR trial in patients with retinal vein occlusion, as well as full primary results from the Phase 3b ELARA trial in patients treated with monthly dosing New presentations include final 64-week results from the Phase 3 QUASAR trial in patients with retinal vein occlusion, as well as full primary results from the Phase 3b ELARA t...

Regeneron is poised for double-digit revenue and EPS growth in 2026, driven by Dupixent and reduced Eylea headwinds. Dupixent's robust expansion and pipeline successors support Regeneron's long-term growth and mitigate post-exclusivity risks. Eylea's decline is moderating, aided by increased patient support and anticipated label expansions.

Regeneron Pharmaceuticals, Inc. (REGN) Q4 2025 Earnings Call Transcript

Regeneron Pharmaceuticals' executives voiced confidence in its experimental weight-loss drug on Friday, saying added cholesterol-lowering benefits could give the company an edge in an increasingly crowded obesity market.

Regeneron stock took a hit early Friday on its higher-than-expected 2026 cost outlook following a fourth-quarter beat.

U.S. drugmaker Regeneron Pharmaceuticals beat analysts' estimate for fourth-quarter profit on Friday, helped by strong demand for its eczema treatment, Dupixent.

TARRYTOWN, N.Y., Jan. 30, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the fourth quarter and full year 2025 and provided a business update.

Regeneron Pharmaceuticals, Inc. is approaching a pivotal earnings report following a strong JP Morgan Healthcare Conference update. I maintain a Buy rating on REGN, supported by a >16% share price gain since my last note. Despite recent gains, REGN trades well below its ~$1,200 all-time high from August 2024.